This tool allows the users to submit log2-CPM values of mRNA and predict the the TNBC status i.e. lymph node metastatic or non-metastatic employing log2-CPM data of signature mRNAs, resulting from analysis of mRNA-seq data of triple negative breast cancer patients. This method requires log2-CPM values of 15 TNBC biomarker genes in each patient to predict patients's status. The first column is mRNA and in second column expression of corresponding mRNA in terms of log2-CPM value in a particular number of patients.